The swirling controversy around the University of Minnesota Department of Psychiatry and the safety of clinical research seems to be focused on the negative. The university recently announced that clinical trials are being suspended.
But even as the U takes steps to shore up clinical research practices, it's important to remember that, for many families, research offers hope.
In the case of my family, it was a lifesaver.
When I was 9, one of my older sisters began a long struggle with schizophrenia. At that time, in the 1960s, mental illness was often dismissed as being the "mother's fault" — bad upbringing.
Luckily, our parents didn't buy into this view. As a school librarian, my mother started doing research of her own. She learned about a clinical drug trial at the University of Nebraska Medical Center that offered hope to help ease my sister's suffering, to control the voices and delusions from her disease.
My sister was enrolled in an early clinical trial, funded by the drug company Sandoz, for Clozapine.
Clozapine was a controversial drug that was at one point withdrawn by the manufacturer because of serious side effects. But about a decade later, clinical studies showed that the drug was more effective than others for treatment-resistant schizophrenia. In 2002, it was approved by the FDA to reduce the risk of suicide.
My sister was part of those trials, and she played a role in helping move schizophrenia from a condition with no treatment or hope to one now understood as a brain chemical imbalance.